Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer

Genetics and Molecular Research

Volumn 13, Issue 3, 2014, Pages 5285-5291

  Liu, P ^a   Yang, D Q ^a   Xie, F ^a   Zhou, B ^a   Liu, M ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Anastrozole; Aromatase inhibitor; Bone pain; Breast cancer; Calcitonin

Indexed keywords

ALKALINE PHOSPHATASE; ANASTROZOLE; AROMATASE INHIBITOR; CALCITONIN; CALCIUM; CALCIUM CARBONATE; OSTEOCALCIN; PHOSPHORUS; SALCATONIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BONE DENSITY CONSERVATION AGENT; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANASTROZOLE INDUCED BONE PAIN; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BONE DENSITY; BONE MASS; BONE PAIN; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL ANALOG SCALE; AGED; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; FEMALE; MIDDLE AGED; OSTEOPOROSIS; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; SPINE;

ABSORPTIOMETRY, PHOTON; AGED; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCITONIN; CALCIUM; FEMALE; FEMUR; HUMANS; MIDDLE AGED; NITRILES; OSTEOCALCIN; OSTEOPOROSIS; PAIN; PHOSPHORUS; SPINE; TRIAZOLES;

EID: 84905055048     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.July.24.7     Document Type: Article

References (23)

1. Belfield A and Goldberg DM (1971). Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme12: 561-573.
2. Berne RM and Levy MN (1990). Fisiologia. 2nd edn. Guanabara, Rio de Janeiro.
3. Body JJ, Bergmann P, Boonen S, Boutsen Y, et al. (2007). Management of cancer treatment-induced bone loss in early breast and prostate cancer-a consensus paper of the Belgian Bone Club. Osteoporos. Int.18: 1439-1450.
4. Cooper C (1997). The crippling consequences of fractures and their impact on quality of life. Am. J. Med.103: 12S-17S.
5. Copp DH, Cameron EC, Cheney BA, Davidson AG, et al. (1962). Evidence for calcitonin-a new hormone from the parathyroid that lowers blood calcium. Endocrinology70: 638-649.
6. Cuzick J, Sestak I, Baum M, Buzdar A, et al. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for earlystage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol.11: 1135-1141.
7. Grahame-Smith DG and Aronson JK (2002). The Drug History and the Clinical Examination and Investigation of Drug Effects. In: The Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd edn (Graheme-Smith DG and Aronson JK, eds.). Oxford University Press, Oxford, 167-170.
8. Hadji P (2009). Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit. Rev. Oncol. Hematol.69: 73-82.
9. Hoff AO and Gagel RF (2005). Osteoporosis in breast and prostate cancer survivors. Oncology 19: 651-658.
10. Hollinger J and Wong ME (1996). The integrated processes of hard tissue regeneration with special emphasis on fracture healing. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.82: 594-606.
11. Hoskin PJ (1995). Radiotherapy for bone pain. Pain63: 137-139.
12. Jacox A, Carr DB, Payne R, Berde CB, et al. (1994). Management of Cancer Pain. Clinical Practice Guideline No 9. Agency for Health Care Policy and Research, US Department of Health and Human Services, Rockville, 41-74.
13. Jiang Y, Huang XE, Yan PW, Cui L, et al. (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy. Asian Pac. J. Cancer Prev.11: 1059-1062.
14. Li Y, Tang JH, Huang XE and Li CG (2011). Clinical comparison on the safety and efficacy of fluorouracil/pirarubicin/ cyclophosphamide (FPC) with fluorouracil/epirubicin/cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac. J. Cancer Prev.12: 1795-1798.
15. Lussier D, Huskey AG and Portenoy RK (2004). Adjuvant analgesics in cancer pain management. Oncologist9: 571-591.
16. Parfitt K (1999). Martindale: the complete drug reference. 32nd edn. Pharmaceutical Press, London, 1257-1258.
17. Reginster JY, Azria M, Gaspar S, Bleicher M, et al. (1992). Endogenous production of specific antibodies does not decrease hypocalcemic response to calcitonin in young rabbits. Calcif. Tissue Int.50: 518-520.
18. Reginster JY (1991). Effect of calcitonin on bone mass and fracture rates. Am. J. Med.91: 19-22.
19. Siligardi G, Samori B, Melandri S, Visconti M, et al. (1994). Correlations between biological activities and conformational properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur. J. Biochem. 221: 1117-1125.
20. Tugwell P, Wells G, Shea B and Peterson J (2003). Hormone Replacement Therapy for Osteoporosis in Postmenopausal Women (Protocol for a Cochrane Review). The Cochrane Library, Oxford: Update Software, 3.
21. Wong R and Wiffen PJ (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst. Rev. CD002068.
22. Young G, Marcus R, Minkoff JR, Kim LY, et al. (1987). Age-related rise in parathyroid hormone in man: the use of intact and midmolecule antisera to distinguish hormone secretion from retention. J. Bone Miner. Res.2: 367-374.
23. Zojer N, Keck AV and Pecherstorfer M (1999). Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf.21: 389-406